BPC-157 vs Thymosin Beta-4
Side-by-Side Comparison
| Attribute | Bpc 157 | Thymosin Beta 4 |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Mechanism | BPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and... | Thymosin beta-4 is the primary intracellular G-actin sequestering protein, maintaining actin monomer pools and regulating cytoskeletal dynamics essential for cell migration. |
| Evidence Rating | C — Phase I–II Clinical Trials | B — Phase III / NDA Filed |
| Clinical Status | Research-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway. | Multiple Phase II and Phase III clinical trials for ophthalmic indications. No full FDA approval yet. |
| Safety Profile | No completed randomized controlled human clinical trials for safety assessment; Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology | RGN-259 ophthalmic solution was well-tolerated in clinical trials with no significant drug-related adverse events; A safety-focused study in 40 healthy adults receiving injectable Tβ4 found minimal adverse effects |
| Route | Subcutaneous (preferred), Intramuscular, or Oral | Subcutaneous (systemic) or Topical/Ophthalmic |
| Dose Range | 200–600 mcg/day SC; oral doses studied at 1–6 mg in clinical trials | SC: 750–2000 mcg/day; Ophthalmic (RGN-259): 0.1% solution 2 drops 2x daily |
| Frequency | Once daily | SC: Once daily; Ophthalmic: 2x daily |
| Molecular Weight | ~1419.5 g/mol | ~4963.5 g/mol |
| Half-Life | ~15 min IV (animal data); oral activity persists 24+ hours | N/A |
Overview
BPC-157 and Thymosin Beta-4 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
BPC-157 — Mechanism & Evidence
BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol) derived from a protein found in human gastric juice. It has demonstrated robust regenerative and cytoprotective effects across hundreds of animal studies spanning tendon, ligament, muscle, bone, nerve, GI tract, and blood vessel healing. However, human clinical data is extremely limited — only three pilot studies have examined BPC-157 in humans as of 2025 (knee pain n=16, interstitial cystitis n=12, IV safety n=2). The FDA classifies it as Category 2, prohibiting compounding, and WADA bans its use in sports.
Key claims: Accelerates tendon and ligament healing; Heals gut lining and treats leaky gut; Reverses NSAID-induced GI damage.
Thymosin Beta-4 — Mechanism & Evidence
Thymosin beta-4 (Tβ4) is a naturally occurring 43-amino acid protein found in virtually all human and animal cells. It is the most abundant member of the beta-thymosin family and plays fundamental roles in cell migration, wound healing, and tissue repair. Tβ4 is distinct from TB-500, which is a synthetic peptide containing only the active heptapeptide region (Ac-LKKTETQ) of Tβ4. The full-length protein is being developed as RGN-259 (RegeneRx Biopharmaceuticals) eye drops for dry eye, neurotrophic keratopathy, and other ophthalmic conditions, with multiple Phase II/III clinical trials completed or ongoing.
Key claims: Promotes corneal wound healing; Reduces dry eye symptoms; Promotes cardiac repair after injury.
Shared Research Applications
These peptides target different research areas. BPC-157 focuses on Injury Recovery, Gut Health, while Thymosin Beta-4 targets Wound Healing, Ophthalmic Research.
Safety Considerations
BPC-157: No completed randomized controlled human clinical trials for safety assessment Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.
Thymosin Beta-4: RGN-259 ophthalmic solution was well-tolerated in clinical trials with no significant drug-related adverse events A safety-focused study in 40 healthy adults receiving injectable Tβ4 found minimal adverse effects Topical (eye drop) administration has minimal systemic exposure
Related Products
Related Research News
BPC-157 Gut Health: Gastric Cytoprotection Studies
Research on BPC-157 began with gastric cytoprotection in the early 1990s, led by Sikiric and colleagues at the University of Zagreb. Studies show it protects against ethanol-induced lesions and NSAID damage in rat models, with effects linked to angiogenesis, prostaglandins, nitric oxide, and gut-brain signaling. This body of work highlights its stability for oral use and broad preclinical applications in GI models.
BPC-157 Shelf Life: Lyophilized vs Reconstituted Stability Guide
BPC-157 has a finite shelf life that varies by form and storage. Lyophilized powder lasts 12-18 months refrigerated or 24+ months frozen, while reconstituted solution holds for about 28 days under refrigeration. Factors like temperature, light, and handling influence stability, and researchers should watch for signs of degradation to ensure reliable results.
TB-500: Thymosin Beta-4's Role in Healing and Repair
TB-500, known as thymosin β4, is a 43-amino-acid peptide first isolated from calf thymus in 1966 by Goldstein et al. It regulates actin in the body, supporting processes like wound healing, angiogenesis, and inflammation control. Research highlights its potential in treating conditions such as myocardial infarction, corneal injuries, and lung damage.